The core generic pharma business of Strides is led by IP-driven product licensing and marketing and distribution partnerships across the globe. We have leveraged our expertise in niche, difficult-to-develop and manufacture products to emerge as a preferred provider of solutions to global pharma majors. Strides has created an exhaustive pipeline of generics across varied formats and domains including oral dosage forms and topicals. We are one among the leading players worldwide in soft gel capsules.
Our domain strategy of developing a comprehensive product portfolio in complex therapeutic segments such as immune-suppressants, anti-virals, high-end antibiotics has attracted marquee partnerships in Regulated markets such as US, UK, Australia and S. Africa. The partnerships we have forged with major pharma players have provided an opportunity for Strides to play an increasingly important role in the global pharma industry. As a next step Strides is enhancing its front-end operations in US and UK to be better positioned to seize new opportunities.
Our product pipeline in Pharma Generics is guided by our strategic intent in developing IP-led generics and unique soft-gel based formulations for prescription, OTC and nutraceutical markets. We are also identifying products for migration to soft gel format.
Our product requirements are supplied by two world-class manufacturing facilities near Bangalore, India and Milan, Italy. The one million square foot soft gel facility at Bangalore is one of the largest of its kind in the world with an annual capacity of 2.5 billion soft gel capsules. With over two decades of experience, we are amongst the world’s leading manufacturers of soft gel capsules. The facility has been approved by US-FDA, MHRA, ANVISA, TGA and MCC. The BELTAPHARM facility in Milan is dedicated to the manufacture of semi-solids (ointments and crèmes) and is approved both by the EU and US-FDA.
Finally, our relentless focus on globally competitive quality and efficient deliveries has earned us the loyalty of customers in 75 countries worldwide.